Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A0BL849
Tue, 02.01.2024
Vita 34 AG
Vita 34 downsizes Management Board until further notice
CFO Dirk Plaga stepped down from the Management Board as of 31 December 2023
Management Board to be temporarily reduced from three to two members
Leipzig, 2 January 2024 – Vita 34 AG, the leading cell bank in Europe and the third largest in the world, is making changes to its Management Boar [ … ]
Fri, 24.11.2023
Vita 34 AG
Vita 34 increases revenue and earnings in Q3 2023 and further stabilizes business development
Revenues increased solidly by 11.7 percent to EUR 56.7 million in the first nine months of 2023
Adjusted pricing models and internal efficiency programs provide positive impetus
EBITDA further improved versus last year and versus Q2 to EUR 3.6 million
[ … ]
Thu, 31.08.2023
Vita 34 AG
Vita 34 stabilizes business development in the second quarter and noticeably improves earnings
Revenues in the first half of 2023 up 13.0 percent to EUR 36.3 million
EBITDA significantly increased to EUR 1.6 million compared with both the previous year and the first quarter of 2023
Operating cash flow significantly improved to EUR 2.9 million
G [ … ]
Wed, 31.05.2023
Vita 34 AG
Vita 34 successfully implements price increases in first quarter of 2023 in generally weak market environment
First quarter sales up 15.7 percent to EUR 17.9 million
Gross profit benefits from price adjustments and cost discipline and increases by 58.2 percent to EUR 5.7 million
EBITDA in positive territory at EUR 0.3 million after significantly [ … ]
Wed, 31.05.2023
Vita 34 AG
Vita 34 successfully implements price increases in first quarter of 2023 in generally weak market environment
First quarter sales up 15.7 percent to EUR 17.9 million
Gross profit benefits from price adjustments and cost discipline and increases by 58.2 percent to EUR 5.7 million
EBITDA in positive territory at EUR 0.3 million after significantly [ … ]
Fri, 12.05.2023
Vita 34 AG
Vita 34 Starts Recruitment for Clinical Trial with CAR-T Drug Candidate
Approval by responsible authorities and ethics committee granted
Recruitment of the first patient imminent
Completion of Phase I expected by the end of 2023
Leipzig, 12 May 2023 - Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), the leading cell bank in Europe and the third lar [ … ]
Fri, 12.05.2023
Vita 34 AG
Vita 34 Starts Recruitment for Clinical Trial with CAR-T Drug Candidate
Approval by responsible authorities and ethics committee granted
Recruitment of the first patient imminent
Completion of Phase I expected by the end of 2023
Leipzig, 12 May 2023 - Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), the leading cell bank in Europe and the third lar [ … ]
Sun, 30.04.2023
Vita 34 AG
Development of Vita 34 AG in 2022 stressed by weakened consumption power of consumers along with one-off effects
Group revenue of EUR 68.9 million 142.6 percent above previous year after merger with PBKM FamiCord (Guidance: EUR 65 to 72 million)
EBITDA of EUR -3.6 million, mostly due to one-off effects under IFRS-15 (Guidance: EUR -6.0 to -3.0 mi [ … ]
Sun, 30.04.2023
Vita 34 AG
Development of Vita 34 AG in 2022 stressed by weakened consumption power of consumers along with one-off effects
Group revenue of EUR 68.9 million 142.6 percent above previous year after merger with PBKM FamiCord (Guidance: EUR 65 to 72 million)
EBITDA of EUR -3.6 million, mostly due to one-off effects under IFRS-15 (Guidance: EUR -6.0 to -3.0 mi [ … ]
Tue, 22.11.2022
Vita 34 AG
Vita 34 benefits from increasing normalization in its core business in the third quarter
Revenues for the first nine months rose to EUR 50.8 million; business development gains further momentum in the third quarter
EBITDA of EUR -1.6 million in the first nine months below previous year due to continued investments in the new activities, but alrea [ … ]